KPV
Lysine-Proline-Valine / Alpha-MSH Fragment
KPV is a three-amino-acid peptide (Lys-Pro-Val) from the end of alpha-MSH. In cell and mouse studies it calmed NF-κB inflammatory signaling and reduced colitis, including when given by mouth. No human trials have been published, and it is not FDA-approved.
Half-life
Not established in humans
Typical Dose
200–500 mcg/day
300/500Route
oral
Category
immune
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How KPV is dosed in practice
Usually taken by mouth. Typical range: 200–500 mcg/day. Half-life: Not established in humans. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Increasingly used in functional medicine for gut inflammation, IBD support, and systemic anti-inflammatory protocols. KPV oral route targets GI tract directly. Often combined with subcutaneous BPC-157 (abdominal injection) for a comprehensive gut-healing stack. Note: oral BPC-157 is ineffective — always use SubQ.
- Functional medicine gut healing protocols
- Peptide therapy for IBD — practitioner case reports
- Alpha-MSH fragment research reviews
Community users report significant reduction in GI inflammation symptoms, skin inflammation, and autoimmune flares. Oral bioavailability debated but anecdotally effective. Some users combine oral and subcutaneous routes.
- Community self-reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for KPV and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Immunosuppressed patients (further immune modulation risk)
- Pregnancy or breastfeeding
- Active infections requiring full immune response
KPV: common questions
What is KPV?
KPV is a three-amino-acid peptide (Lys-Pro-Val) from the end of alpha-MSH. In cell and mouse studies it calmed NF-κB inflammatory signaling and reduced colitis, including when given by mouth. No human trials have been published, and it is not FDA-approved.
How is KPV dosed?
KPV is usually taken by mouth. Typical range in DoseCraft's library: 200–500 mcg/day. Expert (practitioner protocols): 200–500 mcg daily; Once daily (oral, empty stomach); 4–8 weeks. Experimental (early or animal data): 500 mcg daily oral or 200 mcg SubQ; Once daily; 6–8 weeks. These ranges describe what has been studied or used; they are not a prescription.
Is KPV FDA-approved?
No. KPV is not approved by the FDA for any use in people.
What is the half-life of KPV?
DoseCraft's library lists a half-life of Not established in humans. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use KPV?
Listed contraindications: Immunosuppressed patients (further immune modulation risk); Pregnancy or breastfeeding; Active infections requiring full immune response.
Free Guides for KPV
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.